company background image
APPH logo

Apontis Pharma XTRA:APPH Stock Report

Last Price

€6.00

Market Cap

€50.0m

7D

-9.1%

1Y

-36.3%

Updated

23 Feb, 2024

Data

Company Financials +

APPH Stock Overview

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany.

APPH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Apontis Pharma AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Apontis Pharma
Historical stock prices
Current Share Price€6.00
52 Week High€12.15
52 Week Low€3.03
Beta1.76
1 Month Change33.33%
3 Month Change61.29%
1 Year Change-36.31%
3 Year Changen/a
5 Year Changen/a
Change since IPO-68.00%

Recent News & Updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Dec 02
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Recent updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Dec 02
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Jul 29
Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Shareholder Returns

APPHDE PharmaceuticalsDE Market
7D-9.1%1.7%1.3%
1Y-36.3%-28.2%2.3%

Return vs Industry: APPH underperformed the German Pharmaceuticals industry which returned -29.9% over the past year.

Return vs Market: APPH underperformed the German Market which returned 0.1% over the past year.

Price Volatility

Is APPH's price volatile compared to industry and market?
APPH volatility
APPH Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement4.7%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: APPH's share price has been volatile over the past 3 months.

Volatility Over Time: APPH's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1946168Bruno Wohlschlegelhttps://apontis-pharma.de

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

Apontis Pharma AG Fundamentals Summary

How do Apontis Pharma's earnings and revenue compare to its market cap?
APPH fundamental statistics
Market cap€49.98m
Earnings (TTM)-€3.18m
Revenue (TTM)€46.13m

1.1x

P/S Ratio

-15.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APPH income statement (TTM)
Revenue€46.13m
Cost of Revenue€16.79m
Gross Profit€29.34m
Other Expenses€32.52m
Earnings-€3.18m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-0.38
Gross Margin63.60%
Net Profit Margin-6.90%
Debt/Equity Ratio0%

How did APPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.